July 2016- Volume 12, Issue 7

July 2016

In this Issue

Business & Government Policy

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

For your approval

For your approval

A collection of recent regulatory approvals and other actions globally

Patent Docs: BIO International Convention Wrap-up

Patent Docs: BIO International Convention Wrap-up

Kevin Noonan takes a look at intellectual property- and patent-related activity at the recent meeting of the Biotechnology Innovation Organization

A medley of M&As

A medley of M&As

Though the ongoing Sanofi/Medivation struggle drags on, multimillion-dollar deals are still getting done

Brexit could mean big changes for EMA

Brexit could mean big changes for EMA

In addition to challenges potentially facing UK-based companies in wake of electing to leave EU, Britons will likely lose EMA office

Preclinical

Forward momentum in Fragile X

Forward momentum in Fragile X

Anavex reports positive preclinical results with ANAVEX 2-73 in Fragile X

A compelling combination for TNBC

A compelling combination for TNBC

Bavituximab with an anti-PD-1 therapy causes tumor regression and improves survival, immune system activation

A designer drug for breast cancer

A designer drug for breast cancer

Scripps scientists develop cancer-targeting drug that is a ‘clear breakthrough’ in precision medicine

DepoVax vaccine may improve efficacy of checkpoint inhibitors

DepoVax vaccine may improve efficacy of checkpoint inhibitors

Data show control of cancer in advanced tumors previously non-responsive to PD-1 blockades alone

Natural killer cell therapy advancing toward first-in-human clinical trial

Natural killer cell therapy advancing toward first-in-human clinical trial

Fate Therapeutics Inc. presented data on its Adaptive NK Cell Therapy at the Innate Killer Summit 2016 in May in San Diego

Research & Development

Baring the bones

Baring the bones

New 3D constructs enable a closer look at cancer progression in bones

Small entities; big implications

Small entities; big implications

Seres enters into trio of strategic collaborations on infectious disease, immunologic disease and metabolic disease, with particular focus on microbiome research

The impact of inflammation

The impact of inflammation

Risk of autism linked to mother’s immune system dysfunction during pregnancy

Could microbiome research tool revolutionize drug development?

Could microbiome research tool revolutionize drug development?

The University of Luxembourg announces ‘breakthrough’ HuMiX organ-on-a-chip model for the human gastrointestinal tract

Discovery

Addressing the cause of schizophrenia

Addressing the cause of schizophrenia

LDC and Boehringer Ingelheim team up to move beyond merely treating ‘positive symptoms’ of the disease

Is depression a coordinated assault?

Is depression a coordinated assault?

Study suggests depression is driven by networks of genes that span brain circuits

Next-generation mapping for genomic assemblies

Next-generation mapping for genomic assemblies

Study published in Nature Methods describes use of BioNano Irys with Illumina-based NGS methods

Answers about alpha- synuclein

Answers about alpha- synuclein

University of Pittsburgh team uncovers the cause of alpha-synuclein toxicity in Parkinson’s

Contract Services

Horizon, Ubiquigent partner with focus on ubiquitin

Horizon, Ubiquigent partner with focus on ubiquitin

Ubiquitin modification plays key roles in homeostasis, cell signaling

Moving on up

Moving on up

ClinTec adds offices in Spain, hires new manager

MuScreen comes on scene

MuScreen comes on scene

Crown launches platform to expand in-vivo efficacy research of immuno-oncology agents

PPD gains some recognition and a new face

PPD gains some recognition and a new face

PPD announced in June that it had been named best contract research organization in the Triangle Business Journal’s 2016 Life Sciences Awards

Diagnostics

The apnea connection

The apnea connection

Study illuminates link between myocardial fibrosis and obstructive sleep apnea

An ally against colon cancer

An ally against colon cancer

Novigenix reports validation data on Colox blood test for colorectal cancer

Myriad acquires Sividon Diagnostics

Myriad acquires Sividon Diagnostics

Move strengthens product portfolio with breast cancer prognostic test EndoPredict

Confirmation for ConfirmMDx

Confirmation for ConfirmMDx

Multicenter validation study indicates ConfirmMDx stratifies risk for aggressive prostate cancer

Clinical Trials

Phase 1 pass for APG101

Phase 1 pass for APG101

Data shows APG101 decreases necessary transfusions in low to intermediate-1 risk transfusion-dependent MDS patients

Adamas steps up

Adamas steps up

Phase 2 study shows ADS-5102 offers improvement for MS patients with walking impairment

Answering an urgent need

Answering an urgent need

Data on AbbVie SCLC antibody-drug conjugate are presented at ASCO

Changing focus

Changing focus

Marinus Pharmaceuticals now concentrates on status epilepticus and pediatric orphan indications

One last study in LEMS

One last study in LEMS

Catalyst inches closer to FDA approval for Firdapse

Editor's Focus

Exposing that murderous ole FDA

Exposing that murderous ole FDA

The 'FDA Death Meter' website is a great example of why people with an agenda and with minimal understanding of statistics should not be allowed anywhere near stats to make a point

Commentary

Out of order: The cost of a free market

Out of order: The cost of a free market

Maybe it's time for the federal government to get into the business of funding (and perhaps even spearheading) antibiotic discovery and development, since this is an area where the free market seems to be falling short

Newly published PLOS paper calls for better sharing of genomic data

Newly published PLOS paper calls for better sharing of genomic data

Better data sharing would improve research, providing benefits for patients, clinicians and researchers

Special Reports

Special Report on Cell Biology: Sweetening the pot

Special Report on Cell Biology: Sweetening the pot

Is improved understanding of glycobiology the secret to improved biologics?

Q&A

Q&A: Small molecules and the cancer landscape

Q&A: Small molecules and the cancer landscape

Dr. Thomas Dubensky, chief scientific officer at Aduro Biotech, talks about small-molecule therapeutics, immuno-oncology, the STING pathway and more
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue